Literature DB >> 19259905

[Bronchoscopic lung volume reduction in patients with severe homogeneous lung emphysema: a pilot study].

R Eberhardt1, C P Heussel, M Kreuter, O Weinheimer, F J F Herth.   

Abstract

BACKGROUND AND
OBJECTIVE: After bronchoscopic lung-volume reduction (LVR) improvement in pulmonary function and exercising tolerance can be achieved in patients with severe heterogeneous lung emphysema. Feasibility and safety for one-way valve placement in homogeneous emphysema were evaluated. PATIENTS AND METHODS: Ten patients entered this prospective study. In all cases a homogeneous distribution was confirmed by computer analysis of the CT-scans. We performed unilateral LVR and occluded the lobe with the lowest perfusion, measured by nuclear scintigraphy. Endpoints of the study were changes in lung function test, quality of life and 6-minutes-walk-test (6-MWT) at day 30 and 90 and the safety of the procedure.
RESULTS: Preoperative mean forced expiratory volume in 1 second (FEV1) was 0.93 l (range 0.55 - 1.35 l), mean residual volume was 5.23 l (3.55 - 8.24 l) and 6-MWT was 325 m ( 150 - 480 m). Improvement of dyspnoe and exercising tolerance was reported in 7 cases. No major changes in lung function were evident at days 30 and 90. A trend towards improvement was observed in 6-MWT (DeltaMW + 10.4 +/- 9.8 %). One pneumothorax was noticed, in one case the valves were removed after 90 days because of recurrent infections.
CONCLUSIONS: This study shows that bronchoscopic LVR in patients with severe homogeneous emphysema is feasible and seems to be safe. In contrast to surgical LVR patients may have a cinical benefit by bronchoscopic treatment. Longtime follow -up and patient selection criteria have to be examined in larger trials.

Entities:  

Mesh:

Year:  2009        PMID: 19259905     DOI: 10.1055/s-0029-1208076

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

Review 1.  Endoscopic bronchial valve treatment: patient selection and special considerations.

Authors:  Ralf Eberhardt; Daniela Gompelmann; Felix J F Herth; Maren Schuhmann
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-08

2.  Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial.

Authors:  Ralf Eberhardt; Dirk-Jan Slebos; Felix J F Herth; Kaid Darwiche; Manfred Wagner; Joachim H Ficker; Christoph Petermann; Ralf-Harto Hübner; Franz Stanzel; Narinder S Shargill; Arschang Valipour
Journal:  Respiration       Date:  2021-07-23       Impact factor: 3.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.